论文部分内容阅读
碘葡酰胺(Metrizamide Amipaque)是蛛网膜下腔水溶性对比剂——非离子低渗性造影剂,目前似乎是最符合安全标准的。然而随着应用愈来愈多,剂量较大伴发付作用的发生率也相当高,虽然大多数付作用表现较轻微,例如头痛、恶心,但也有更为严重的付作用如各种精神紊乱和抽搐,症状通常发生在大约使用碘葡酰胺4～6小时后,在其后数小时内最严重,但一般不超过24小时,常于48小时内消失。经前瞻性观察,有16～35%受检者脑电图有一过性异常。由于CSF与CNS之间缺乏屏障,能允许水溶性造影剂顺利地扩散进入CNS细胞外间隙导致了造影剂与神经元直接接触。故而付作用可能与造影剂在组织内的浓度有关,组织内的浓度必然与CSF中造影剂的局部浓度及其与神经组织
Metrizamide Amipaque is a subarachnoid water-soluble contrast agent, a non-ionic hypotonic contrast agent, that now appears to be the most consistent safety standard. However, as more and more doses are used, the incidence of concurrent doses is quite high. Although most of the payoffs are less severe, such as headache and nausea, there are more serious side effects such as various mental disorders and Convulsions, symptoms usually occur in about 4 to 6 hours after the use of iodoglycolmide, the most serious in the next few hours, but generally no more than 24 hours, often disappear within 48 hours. After the prospective observation, 16 ~ 35% of the subjects had a transient EEG abnormalities. Due to the lack of a barrier between CSF and CNS, the ability to allow water-soluble contrast media to diffuse smoothly into the extracellular space of the CNS results in direct contact of contrast media with neurons. Therefore, the effect may be related to the concentration of contrast medium in the tissue, the concentration in the tissue must be associated with the CSF local concentration of contrast medium and nerve tissue